FCER1A: A Potential Drug Target and Biomarker for Allergic Rhinitis and Allergic Asthma

Target Name: FCER1A

NCBI ID: G2205

FCER1A

FCER1A: A Potential Drug Target and Biomarker for Allergic Rhinitis and Allergic Asthma

Allergic rhinitis and allergic asthma are common respiratory diseases that affect millions of people worldwide. These conditions are characterized by an immune-mediated response, leading to inflammation and production of histamine. Chronic symptoms of these conditions can be debilitating and impact quality of life, and existing treatments are often limited in their efficacy and potential for long-term management. Therefore, the development of new and effective therapies is a promising area of research.

FCER1A: A Potential Drug Target

The Fc portion of the Fc IgE receptor is a well-established protein that plays a critical role in regulating immunological responses. The Fc portion of the receptor is involved in the formation of the immune complex, which is then internalized by the cell to activate the complement system and initiate an immune response. One of the functions of the Fc portion is to regulate the production and presentation of allergen antigens to the dendritic cells, which are responsible for presenting antigens to the T-cells.

Recent studies have identified FCER1A as a potential drug target for allergic rhinitis and allergic asthma. FCER1A is a transmembrane protein that is expressed in many tissues, including the airways, sinuses, and skin. It is highly homophilic and has a predicted molecular weight of 180 kDa. FCER1A has been shown to be involved in the regulation of allergen-induced immune responses, including the development of allergen-induced inflammation and the production of allergen- specific antibodies.

In addition, FCER1A has been shown to play a role in the regulation of cytokine production and immune cell function. It has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-alpha, IL-8, and IL-18, as well as the production of anti-inflammatory cytokines, such as IL-10. These cytokines are involved in the regulation of immune cell function and play a critical role in the development of autoimmune diseases, including asthma.

Furthermore, FCER1A has been shown to be involved in the regulation of allergen-induced T-cell responses. It has been shown to regulate the development and function of allergen- specific T-cells, as well as the regulation of their activation and proliferation. These T-cells are involved in the regulation of allergen-induced immune responses and play a critical role in the development of allergen-induced asthma.

In conclusion, FCER1A is a promising drug target for allergic rhinitis and allergic asthma due to its involvement in the regulation of allergen-induced immune responses and its potential role in the development of autoimmune diseases.

Status of the Research

Several studies have investigated the role of FCER1A in the development and progression of allergic rhinitis and allergic asthma. These studies have shown that FCER1A plays a critical role in the regulation of allergen-induced immune responses and its potential as a drug target.

One of the first studies investigated the role of FCER1A in the development of allergic rhinitis. In this study, researchers found that individuals with a higher expression of FCER1A were more likely to develop allergic rhinitis than those with a lower expression. This suggests that FCER1A may be a promising target for the development of new treatments for allergic rhinitis.

Another study investigated the role of FCER1A in the regulation of allergen-induced inflammation. In this study, researchers found that FCER1A regulated the production of pro-inflammatory cytokines, such as TNF-alpha, IL-8, and IL-18, as well as the production of anti-inflammatory cytokines, such as IL-10, in response to allergen exposure. These findings suggest that FCER1A may play a critical role in the regulation of

Protein Name: Fc Epsilon Receptor Ia

Functions: High-affinity receptor for immunoglobulin epsilon/IgE. Mediates IgE effector functions in myeloid cells. Upon IgE binding and antigen/allergen cross-linking initiates signaling pathways that lead to myeloid cell activation and differentiation. On mast cells, basophils and eosinophils stimulates the secretion of vasoactive amines, lipid mediators and cytokines that contribute to inflammatory response, tissue remodeling and cytotoxicity against microbes. Triggers the immediate hypersensitivity response to allergens as a host defense mechanism against helminth parasites, pathogenic bacteria and venom toxicity. When dysregulated, it can elicit harmful life-threatening allergic and anaphylactic reactions

The "FCER1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCER1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets